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Background: Squamous cell carcinoma is the most common
malignancy in the lower lip. Although lower lip squamous cell
carcinoma is slow growing, up to 29% of tumors develop metas-
tases to the cervical lymph nodes. Thus, identification of biologi-
cal markers that could provide prognostic information about the
invasive or metastatic potential of these lesions is important. It is
known that angiogenesis, lymphangiogenesis and proliferation
play an important role in tumor progression. Therefore, the goal
of this study was to analyze the immunohistochemical expres-
sion of Ki-67, CD34 and Podoplanin in hyperkeratosis and in squa-
mous cell carcinoma of the lower lip. It was intended to assess
the possibility of using such markers as indicators of morpholog-
ical aggressiveness of squamous cell carcinoma of the lower lip
(LLSCC).
Materials and methods: Seventy-one cases of the lower lip
lesions, obtained from the files of Novosibirsk Regional Oncology
Center were selected for this study. The specimens were divided
into three groups: a lower lip hyperkeratosis group consisting of
22 cases; LLSCC with keratinization consisting of 34 cases and
LLSCC without keratinization consisting of 15 cases. To analyze
angiogenesis, lymphangiogenesis and proliferation, we per-
formed immunostains of the lower lip biopsy material for the
CD34, vascular marker, Podoplanin, lymphatic-specific markers
and Ki-67, marker of proliferation. Tissue samples were fixed
in 10% neutral formalin, processed by standard histological
techniques and embedded in paraffin. All steps of the
immunohistochemical reaction were performed by using
BENCHMARK/XT slide stainer (Ventana). The lymphatic and
blood vessels volume density and Ki-67 cells numerical density
were morphometrically analyzed in all groups and compared
using the non-parametric Mann–Whitney test and the Wilcoxon
signed rank test. A level of significance of 5% (p < 0.05) was
adopted for all tests.
Results: All cases of a lower lip hyperkeratosis and LLSCC were
positive for Ki-67, CD34 and Podoplanin. With respect to the pat-
tern of staining, specimens exhibited a predominantly peripheral
staining for CD34 and Podoplanin in inflammatory infiltrates and
tumor sites. In contrast, staining for Ki-67 was predominantly
central in inflammatory infiltrates and tumor sites in hyperker-
atosis and LLSCC. When compared to lower lip hyperkeratosis,
LLSCC (both with keratinization and without keratinization)
showed a higher number of immunopositive Ki-67 cells (by 64%
and 77%, respectively, p < 0.05). It was found that proliferative
activity of tumor cells in LLSCC with keratinization was 2 times
higher than that in LLSCC without keratinization. Comparison
of the volume density of blood vessels showed that the density
of CD34+ – blood vessels in hyperkeratosis was lower by 77% than
in LLSCC without keratinization and lower by 64% than in LLSCC
with keratinization. At the same time, volume density of blood
vessels in LLSCC without keratinization was higher by 56% than
that in LLSCC with keratinization. Investigation of lymphatic
vessels showed that Podoplanin+ – lymphatic vessels volume
density in hyperkeratosis was lower by 50% than that in LLSCC
without keratinization and lower by 24% than that in LLSCC with
keratinization. Whereas in LLSCC without keratinization the
lymphatic vessels volume density was higher by 51% than that
in LLSCC with keratinization.
Conclusion: This study has shown the greater development of
blood and lymphatic vessels in LLSCC without keratinization in
comparison with hyperkeratosis and LLSCC with keratinization,
thus contributing to the development of metastasis.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.010
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The work describes advantages of our latest instrument
developments in flow cytometry and microscopy. Characteristics
of newly launched flow cytometer, which uses acoustic focusing
to align the cells in the focus of the laser for analysis, allows to
analyze samples at a much higher throughput rate without losing
precision and sensitivity. This opens up new possibilities
regarding sample preparation and analysis. These advantages
we want to demonstrate on 2 examples, whole blood analysis
and rare event analysis. Analysis of biological samples in the
most physiologic state with minimal sample preparation and
manipulation is a key objective to any workflow. However as
whole blood samples generally require significant manipulation,
such as wash/centrifugation steps and/or red blood cell lysis,
we have developed multiple no-lyse, no-wash assays to minimize
these manipulation steps to obtain more physiological results.
Here we show how we utilize the rapid sample collection capabil-
ities of the our instrument to characterize phagocyte function in
human whole blood with a phagocytosis/phagosome acidification
assay and also a dihydrorhodamine 123 superoxide production
assay, in a no-lyse, no wash format.
Another area where our technology can shift boundaries is the
field of rare event analysis. Due to the low frequency of the target
cell population a large number of total events (in the range of
several millions) need to be acquired. Simply due to the enor-
mous amount of data that needs to be acquired, time becomes
a very limiting factor for rare event analysis. As Acoustic Focusing
allows analyzing samples at an approximately 10 higher
throughput rate without scarifying data quality and maintaining
a low coincidence rate, it pushes the limits what can be done in
this field. As an example we will show the characterization of
human iNKT cells.
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In addition to flow cytometry we want to show how modern
microscopes help to perform a variety of routine and specialty
applications.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.011
P124
Targeted bisulfite sequencing of potential prostate cancer cell-free
DNA markers: novel approach to reveal diagnostically significant
molecules
A. Bondara,*, A. Kurilshikova, E. Morozkina,b, M. Zaripovc,
M. Kabilova, V. Voytsitskiyc, V. Vlassova, P. Laktionova,b. a Institute
of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk,
Russian Federation, bNovosibirsk Regional Cancer Center, Novosibirsk,
Russian Federation, cAcademician E.N. Meshalkin Novosibirsk State
Research Institute of Circulation Pathology, Russian Federation
⇑
Corresponding author.
Cancer cells display altered methylation signatures distin-
guishing them from normal cells. Originating from all tissues
and cells of the body cell-free DNA (cfDNA) including aberrantly
methylated DNA reflect epigenetic aberrations occurs not only
in tumor cells but also in tumor microenvironment. Actually,
aberrantly methylated cfDNA has proved to be a promising
biomarker for noninvasive detection of cancer with several
clinically-certified tests (Epi-pro Colon, Epi-pro Lung, Colo-
guard). However only one test (Epi-pro Colon) uses blood
plasma – the most convenient source of cfDNA. Input of tissue
and age specific methylation along with unidentified reasons lead
to the presence of molecules with every conceivable cytosine-
methylation patterns which decrease probability of tumor DNA
identification. Among numerous variants of cfDNA methylation
patterns only few reflect cancer related changes. To identify those
tumor-specific profiles single nucleotide resolution of methylated
cytosine locations in the individual circulating DNA molecules is
obviously required.
We performed target bisulfite sequencing of potential prostate
cancer (PC) cfDNA markers (GSTP1; RNF219) isolated from blood
plasma of 18 healthy donors (HD), 17 benign hyperplasia (BPH)
and 20 PC patients using MiSeq platform (Illumina). RNF219 gene
was shown to have high diagnostic potential in our previous
comparative study of cfDNA from HD, PC and BHP patients using
HCGI12k microarrays (Cortese, et al., 2012). GSTP1 is a common
pathological DNA methylation event in PC and is most widely
studied and promising methylation marker in the cfDNA of PC
patients (Wu, et al., 2011).
Selected loci were amplified after bisulfite conversion (Zymo
Research) of cfDNA with methyl-independent barcoded primers
and sequenced with coverage ranging from 23509 to 143953.
Identification of CpG methylation status in DNA fragments was
performedwith the BiQ Analyzer HT Software. All statistical anal-
ysis was performed using R Statistical Software (version 3.1.1) To
reveal diagnostically significant differences, several approaches
to data analysis were used. Conventional approach is a prediction
of patient’s diagnosis based on differences in methylation level
of CpG-sites. Another approach used in this study relies on
discrimination of cancer-related correlation between methylation
statuses of CpG-sites within individual molecules of cfDNA –
Intramolecular Correlation of Methylation Statuses (ICoMS).
Study population was randomly subsampled into training and
test cohorts. The logit regression model based on methylation
level of CpG-sites achieved an area under the ROC curve (AUC)
exceeding 0.94 in both cohorts for GSTP1 gene and 0.81 – for
RNF219 gene. A novel approach to identify diagnostic significance
of cfDNA methylation was based on comparison of correlation
matrices (pairwise phi coefficient between methylation statuses
of CpG sites) for HD, BHP and PC groups. Binomial regression
models with LASSO penalization were used to predict patient’s
diagnosis. ROC curves for fitted models show AUC, specificity
and sensitivity as 0.99, 100% and 92% for GSTP1 gene and 0.99,
100% and 90% for RNF219 (test cohort).
The ICoMS approach estimates diagnostic value of target
genes and reveals cancer-related cytosine methylation. That
could potentially input in gene expression, identify the features
of tumor physiology and on a par with conventional approaches
provide helpful information for rational design of noninvasive,
methylation-specific cfDNA-based diagnostics for PC.
Moreover, the planned further evaluation of relationship
between the revealed correlations associated with cancer
and tumor biology could increase the basic knowledge of
carcinogenesis.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.012
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Background: Breast cancer ranks the first among female onco-
logical diseases and ranks the second after lung cancer among
causes of cancer related deaths. Use of contemporary anticancer
drugs significantly enhanced possibilities of cancer therapy.
However, most of medicines against cancer have such disadvan-
tages as toxicity, narrowness of therapeutic action, and
emergence of drug resistance. Recently, an approach based on
potential of dendritic cells (DCs) to induce formation of cytotoxic
T-cell immune response against cancer cells is widely used. Prim-
ing of dendritic cells by DNA-constructs encoding immunogenic
epitopes of tumor antigens is regarded as a rather promising
approach to design cancer vaccines. The aim of this study is to
construct, obtain and study expression in eukaryotic cells of
recombinant plasmid – candidate DNA-vaccines inducing T-cell
immune response against breast cancer.
Materials and methods: Using the PolyCTLDesigner software,
DNA-vaccine construct was made encoding polyepitope T-cell
immunogen BC-A*0201. Gene encoding target immunogen was
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